A MET Targeting Antibody-Drug Conjugate Overcomes Gemcitabine Resistance in Pancreatic Cancer.

CONCLUSIONS: Together these results suggest the promise of agents such as TR1801-ADC as a novel approach to the treatment of pancreatic cancer. PMID: 33451980 [PubMed - as supplied by publisher]

https://www.ncbi.nlm.nih.gov/pubmed/33451980?dopt=Abstract

Source: Clinical Cancer Research - January 15, 2021 Category: Cancer & Oncology Authors: Cazes A, Betancourt O, Esparza E, Mose ES, Jaquish D, Wong E, Wascher AA, Tiriac H, Gymnopoulos M, Lowy AM Tags: Clin Cancer Res Source Type: research